Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma stocks outperform
Mon, 1 Dec 11:30 am

After opening in the green, the Indian indices are trading flat during the morning session amid outperformance in pharma stocks. Engineering and energy stocks are leading the losers today.

The BSE-Sensex is trading up 34 points. The NSE-Nifty is trading up 13 points. The BSE Mid Cap index is trading up 0.3% and the BSE Small Cap index is trading up 0.1%. The rupee is trading at 62.12 to the US dollar.

Most software stocks are trading higher today. Wipro and Tata Consultancy Services (TCS) are leading the gainers. As per a leading financial daily, India's fifth largest IT firm Tech Mahindra, has launched a data analysis platform for auto insurance firms. The software will allow these firms to adjust premiums according to the actual usage patterns of individual drivers. This is a big improvement to the existing system of using industry averages to calculate premiums. Tech Mahindra claims that this solution will help insurers reduce claim costs by up to 20% and premiums by up to 40%. Tech Mahindra has begun marketing the product across geographies with AT&T providing global connectivity for the software. Tech Mahindra was trading up 0.3% at the time of writing.

As per a leading business daily, recently out macro economic data shows that the pace of activity at factories in the country expanded at the fastest pace in almost 2 years during the month of November on the back of rising order books. The rising orders are leading manufacturers to increase output. The Purchasing Managers' Index (PMI) compiled by HSBC rose to 53.3 in November from 51.6 in October. This is its highest level since February 2013. The related survey also revealed that companies have been able to pass on additional input costs to consumers at a faster clip during the month gone by, which bodes well for the earnings of corporate India going forward.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Pharma stocks outperform". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.